NFKB1 and acute myeloid leukemia: In fact, the small molecule NF-κB inhibitor dimethylaminoparthenolide (DMAPT /LC1) has been shown to selectively eradicate AML LSCs in the laboratory [92, 121-123] and is currently evaluated in a phase I-II ‘first in man’ clinical study at Cardiff University, UK (http://medicine.cf.ac.uk/person/dr-steven-knapper/research/).